Lapalieva 250 mg Tablet 30's contains Lapatinib as an active ingredient, which is used in combination with capecitabine for treating patients with HER2-positive advanced or metastatic breast cancer who have received prior treatment. This medicine works by inhibiting the excess production of a human epidermal growth factor receptor 2 (HER2) protein in the mammalian cells. This causes inhibition of the cancer cell growth and, finally, initiation of apoptosis.

FAQs

How does Lapalieva 250 mg Tablet 30's work?

Lapalieva 250 mg Tablet 30's contains Lapatinib, which works by inhibiting the excess production of a protein called human epidermal growth factor receptor 2 (HER2) in mammalian cells. This causes inhibition of the cancer cell growth.

What are the points to be informed to the doctor before starting treatment?

Inform your doctor whether you have received any other breast cancer treatment. Lapalieva 250 mg Tablet 30's may cause left ventricular ejection fraction, hypersensitivity reactions, hepatotoxicity, severe diarrhea, and embryo-fetal toxicity during the treatment. Hence, inform your oncologist if you have any cardiovascular conditions, liver/kidney disease, are pregnant, are planning to become pregnant, or are breastfeeding before taking Lapalieva 250 mg Tablet 30's.

Does Lapalieva 250 mg Tablet 30's cause liver problems?

Hepatotoxicity (liver toxicity) has been reported in clinical studies and postmarketing experience with Lapalieva 250 mg Tablet 30's. Hepatotoxicity can be fatal, and deaths have been reported. The cause of death is unknown. If you have upper stomach pain, itching, dark urine, clay-coloured faeces, or jaundice (yellowing of the skin or eyes), inform your doctor immediately.